U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07439263) titled 'Single Ascending Dose Study of HB2198 in Healthy Participants' on Feb. 18.
Brief Summary: Phase 1, single center, randomized, double blind, placebo controlled SAD study assessing safety, tolerability, PK, PD, and immunogenicity of HB2198 after a single IV infusion in healthy adults. Four dose levels will be explored with sentinel participants per cohort. Approximately 32 participants (6 HB2198:2 placebo per cohort) will be followed for ~2 months, with extended follow up if B-cell counts remain suppressed.
Study Start Date: Feb. 23
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteer
Intervention:
DRUG: HB2198, a Tetravalent...